In 1954, Shaw and co-workers1 introduced a new barbiturate antagonist, β,β-methylethylglutarimide (Megimide). Since then, many reports of its use for the treatment of barbiturate intoxication,2 activation of the electroencephalogram,3 and rapid termination of barbiturate anesthesia4 have appeared in the literature. The most satisfactory results have been obtained in patients who have taken less than 2 gm. of barbiturate and have been in coma for less than 12 hours. Because of the danger of overdosage (vomiting and muscular fasciculation), doses of 1 gm. of β,β-methylethylglutarimide have seldom been exceeded. This drug has been postulated to be either a barbiturate inactivator or a competitor for the same substrate in the brain.
The following case report is presented because of the use of a large dose of β,β-methylethylglutarimide (5.5 gm.) in the treatment of barbiturate intoxication. The electroencephalogram was employed to evaluate the depth of the narcosis and to
Boyan CP, Howland WS, Bellville JW. BETA, BETA-METHYLETHYLGLUTARIMIDE (MEGIMIDE) IN TREATMENT OF BARBITURATE INTOXICATIONREPORT OF A CASE. JAMA. 1957;163(10):835–837. doi:10.1001/jama.1957.82970450001009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: